BIO 2019 Notebook: M&A Soars, Lartruvo Lookback, BIO Vs. ASCO

 
• By Sue Sutter and Joseph Haas

News and views from day four of the BIO International Convention: emerging company M&A deals nearly double in 2018; former FDA official Amy McKee said "everything worked right" with accelerated approval and removal of Lilly's Lartruvo; and the ASCO effect on the 3-6 June BIO meeting.

Bio 2019 Notebook for Scrip
Lartruvo's market removal was a signal that the system works, former FDA official says

More from New Products

More from Scrip